SIVEXTRO®

(tedizolid phosphate) 200 mg injection, for intravenous use; 200 mg tablet, for oral use

Safety

Adverse reactions

Selected adverse reactions occurring in ≥2% of patients in Phase 3 ABSSSI clinical trials

SIVEXTRO (n=662) Linezolid (n=662)
Gastrointestinal disorders
Nausea 8% 12%
Diarrhea 4% 5%
Vomiting 3% 6%
Nervous system disorders
Headache 6% 6%
Dizziness 2% 2%

Discontinuation rates

0.5% of patients receiving SIVEXTRO and 0.9% receiving linezolid discontinued treatment due to adverse reactions.

Hematological abnormalities

Incidence of hematological abnormalities in phase 3 ABSSSI clinical trials 

Potential significant clinical valuesa,b
Laboratory assay SIVEXTRO (n=618)c Linezolid (n=617)c
Hemoglobin (<9 g/dL females; <10.1 g/dL males) 3.1% 3.7%
Platelet count (<112 x 103/mm3) 2.3% 4.9%
Absolute neutrophil count (<0.8 x 103/mm3) 0.5% 0.6%

(a) <75% (<50% for absolute neutrophil count) of lower limit of normal for values normal at baseline.

(b) Represents lowest abnormal post-baseline value through the last dose of active drug.

(c) Number of patients with non-missing laboratory values.

Drug-drug interactions

Increased Breast Cancer Resistance Protein (BCRP) substrate plasma concentrations

SIVEXTRO (tedizolid phosphate), when administered orally, can increase the plasma concentrations of orally administered BCRP substrates. If possible, an interruption in the treatment of the co-administered BCRP substrates should be considered, especially for BCRP substrates with a narrow therapeutic index (eg methotrexate or topotecan). If coadministration cannot be avoided, monitor for adverse reactions related to the concomitantly administered BCRP substrates, including rosuvastatin.

No known interactions with serotonergic agents

Serotonergic effects at doses of tedizolid phosphate up to 30-fold above the human equivalent dose did not differ from vehicle control in a mouse model that predicts serotonergic activity.

In phase 3 trials, subjects taking serotonergic agents including antidepressants were excluded.

No known interactions with adrenergic agents

2 placebo-controlled crossover studies with SIVEXTRO (at steady state) showed no meaningful changes in blood pressure or heart rate with pseudoephedrine, and the median tyramine dose required to cause an increase in systolic blood pressure (≥30 mmHg) was 325 mg with SIVEXTRO compared to 425 mg with placebo.

Palpitations were reported in 21/29 (72.4%) subjects exposed to SIVEXTRO in the tyramine challenge study vs 13/28 (46.4%) of placebo patients.

Monoamine oxidase inhibitors

Tedizolid is a reversible inhibitor of monoamine oxidase (MAO) in vitro. The interaction with MAO inhibitors could not be evaluated in phase 2 and 3 trials, as subjects taking such medications were excluded from the trials.

Indication

Indication: SIVEXTRO is an oxazolidinone-class antibacterial indicated for the treatment of adults with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillin-susceptible [MSSA] isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus group (including Streptococcus anginosus, Streptococcus intermedius and Streptococcus constellatus), and Enterococcus faecalis.

Usage: To reduce the development of drug-resistant bacteria and maintain the effectiveness of SIVEXTRO and other antibacterial drugs, SIVEXTRO should be used only to treat ABSSSI that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Selected Safety Information

Patients with neutropenia: The safety and efficacy of SIVEXTRO in patients with neutropenia (neutrophil counts <1000 cells/mm3) have not been adequately evaluated. In an animal model of infection, the antibacterial activity of SIVEXTRO was reduced in the absence of granulocytes. Alternative therapies should be considered when treating patients with neutropenia.

Clostridium difficile–associated diarrhea (CDAD), ranging from mild diarrhea to fatal colitis, has been reported with nearly all systemic antibacterial agents, including SIVEXTRO. Evaluate all patients who present with diarrhea following antibiotic use. Careful medical history is necessary because CDAD has been reported to occur more than two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, antibacterial use not directed against C. difficile should be discontinued, if possible.

Development of drug-resistant bacteria: Prescribing SIVEXTRO in the absence of a proven or strongly suspected bacterial infection or prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

Adverse reactions: The most common adverse reactions for SIVEXTRO are nausea (8%), headache (6%), diarrhea (4%), vomiting (3%), and dizziness (2%). Infusion site reactions (phlebitis) have been reported (3.1%) in patients receiving SIVEXTRO (when administered intravenously), particularly among Asian patients.

Drug interactions with BCRP substrates: SIVEXTRO (when administered orally) can increase the plasma concentrations of orally administered Breast Cancer Resistance Protein (BCRP) substrates and the potential for adverse reactions. Monitor for adverse reactions related to the concomitant BCRP substrates if coadministration cannot be avoided.

Before prescribing SIVEXTRO, please read the accompanying Prescribing Information. The Patient Information also is available.

AINF-1180496-000404/18